Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

23Andme Holding Co. (ME)

23Andme Holding Co. (ME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
3 Ultra-High-Yield Dividend Stocks to Buy Hand Over Fist Right This Instant

Business development companies can be a lucrative source of passive income.

DOCU : 55.89 (+2.38%)
LYFT : 12.34 (-0.72%)
ME : 0.4420 (-6.79%)
HTGC : 21.18 (-0.05%)
HRZN : 12.15 (-0.41%)
ARCC : 20.71 (-0.67%)
Why 23andMe Stock Tumbled 10% on Tuesday

Is altruism a good idea for an unprofitable capitalistic enterprise?

ME : 0.4420 (-6.79%)
This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be Next

Matterport is being acquired by a real estate giant, but it might not be the last ex-SPAC to go this route.

MTTR : 4.29 (unch)
CSGP : 74.40 (-1.16%)
KIND : 2.76 (unch)
ME : 0.4420 (-6.79%)
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?

Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023.

ME : 0.4420 (-6.79%)
GSK : 39.35 (-0.03%)
A Few Years From Now, You'll Probably Wish You'd Followed Billionaire Investors Into This Stock

Nu Holdings went from an idea to a $50 billion business over a handful of years. Several billionaire investors are betting on even more upside.

BRK.AX : 0.012 (unch)
SQ : 68.10 (+0.15%)
SNOW : 129.85 (+0.01%)
META : 476.79 (+0.20%)
AAPL : 224.31 (+0.06%)
OKTA : 94.03 (+0.12%)
ZM : 58.87 (-0.47%)
ABNB : 147.99 (+0.76%)
DASH : 106.10 (+5.80%)
ME : 0.4420 (-6.79%)
CART : 35.00 (unch)
NU : 13.47 (+2.75%)
Is 23andMe Stock a Smart Buy Right Now?

It's having trouble getting its core business model to work.

ME : 0.4420 (-6.79%)
The 3 Worst Stock Investments I Ever Made -- and What I Learned From Them

Not all of my investments have been winners. Here are three that went badly and the important lessons I learned from them.

ME : 0.4420 (-6.79%)
LTCH : 0.4000 (+5.26%)
AAPL : 224.31 (+0.06%)
TSLA : 239.20 (-4.02%)
IBM : 183.25 (-1.06%)
SHOP : 63.16 (+0.08%)
MELI : 1,649.99 (+1.65%)
T : 19.12 (-0.16%)
INVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation Of 23andMe Holding Co (ME) Data Breach

New York, New York--(Newsfile Corp. - December 7, 2023) - 23andMe, a popular personal genomics and DNA analysis company run by 23andMe Holding Co. ("23 and Me") (NASDAQ: ME), recently suffered a massive...

ME : 0.4420 (-6.79%)
Why Pancreatic Cancer is No Longer a Death Sentence: Emerging Therapies to Watch

USA News Group – Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully...

ONCY : 1.0300 (unch)
ONC.TO : 1.41 (+0.71%)
LLY : 857.47 (+1.01%)
RHHBY : 39.2700 (-0.18%)
BNTX : 85.46 (-1.05%)
ME : 0.4420 (-6.79%)
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END

LLY : 857.47 (+1.01%)
ONCY : 1.0300 (unch)
ONC.TO : 1.41 (+0.71%)
RHHBY : 39.2700 (-0.18%)
BNTX : 85.46 (-1.05%)
ME : 0.4420 (-6.79%)

Barchart Exclusives

Why One Analyst Says Palantir Stock is a Sell Ahead of Earnings
Despite Palantir's impressive 66% surge this year, Mizuho downgraded the stock to 'Underperform' due to concerns over high valuation and limited earnings visibility. With mixed analyst ratings and the Q2 earnings report approaching, investors are advised to tread carefully and prepare for potential volatility. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar